X

Drug Profile

VVN 001

Alternative Names: VVN-001; VVN001 Ophthalmic Solution

Latest Information Update: 24 Mar 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator VivaVision Biotech
Class Eye disorder therapies
Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Dry eyes

Most Recent Events

22 Mar 2022 Phase-II clinical trials in Dry eyes in China (Ophthalmic)
22 Mar 2022 Topline efficacy and safety data from a phase II trial in dry eyes released by VivaVision Biotech
22 Mar 2022 VivaVision Biotech completes a phase I pharmacokinetic trial in healthy volunteers in China (Ophthalmic) prior to March 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com